2018 Licensing Pharmacokinetics 
New Drug Approvals
OCTOBER 12, 2024
Alzheon licensed ALZ-801 from NeuroChem and is developing it for Alzheimer’s disease. 2018; 32(9): 849–861. [2]. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease. Clin Pharmacokinet. 2018 Mar;57(3):315-333. Hey JA, et al.
The Pharma Data
DECEMBER 13, 2020
MacroGenics , based in Rockville, Maryland, has a target action date of December 18 for its Biologics License Application (BLA) for margetuximab in combination with chemotherapy for patients with metastatic HER2+ breast cancer. Read on for this week’s. MacroGenics’ Margetuximab for Metastatic HER2+ Breast Cancer.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Practical Cheminformatics
DECEMBER 7, 2023
It is rare for graduate students to be exposed to tasks like optimizing pharmacokinetics or off-target binding. In these cases, broadening your skillset into other areas like medicinal chemistry, pharmacology, biophysics, pharmacokinetics, and disease biology is important. Mark Murcko’s 2018 paper in J Med.
New Drug Approvals
SEPTEMBER 29, 2024
2018 ; Ding et al., According to a company press release and a poster presentation at the 2018 CTAD conference, healthy adults received 25, 50, or 100 mg COR388 or placebo every 12 hours for 10 days; AD patients took 50 mg or placebo every 12 hours for 28 days. Epub 2018 Oct 3 PubMed. Epub 2018 Jan 30 PubMed.
The Pharma Data
AUGUST 22, 2021
Discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020, the human monoclonal antibodies bind to distinct sites on the SARS-CoV-2 spike protein(7) and were optimised by AstraZeneca with half-life extension and reduced Fc receptor and complement C1q binding. 2018; 37(9): 886-892. About AstraZeneca.
The Pharma Data
DECEMBER 21, 2020
UBX1325 is developed from BM-962, a Bcl-xL inhibiting compound licensed to UNITY by Ascentage Pharma for the treatment of age-related diseases. This progress in clinical development qualifies Ascentage Pharma for a milestone payment according to the terms of the licensing agreement. SUZHOU, China and ROCKVILLE, Md. ,
The Pharma Data
NOVEMBER 8, 2020
The submission includes data from the ENLIGHTEN clinical development program in schizophrenia, and pharmacokinetic (PK) bridging data comparing ALKS 3831 and Zyprexa (olanzapine), to support an indication for schizophrenia. Celgene acquired it in 2018 from bluebird bio, who originally developed the therapy.
Expert insights. Personalized for you.
62 
Let's personalize your content